Next Article in Journal
Membrane Activity and Channel Formation of the Adenylate Cyclase Toxin (CyaA) of Bordetella pertussis in Lipid Bilayer Membranes
Next Article in Special Issue
Anatomical Considerations When Treating Compensatory Hypertrophy of the Upper Part of the Masseter after Long-Term Botulinum Neurotoxin Type A Injections
Previous Article in Journal
Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties
Open AccessArticle

Botulinum Toxin Therapy for Managing Sleep Bruxism: A Randomized and Placebo—Controlled Trial

1
Department of Oral Medicine, College of Dentistry, Wonkwang University, Daejeon 35233, Korea
2
Department of Orofacial Pain and Oral Medicine, Yonsei University Dental Hospital, Seoul 03722, Korea
3
TMJ & Orofacial Pain Clinic, Los Angeles, CA 90006, USA
4
Seoul Sleep Clinic, Seoul 06052, Korea
5
Department of Orofacial Pain and Oral Medicine, College of Dentistry, Yonsei University, Seoul 03722, Korea
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(3), 168; https://doi.org/10.3390/toxins12030168
Received: 20 February 2020 / Revised: 5 March 2020 / Accepted: 7 March 2020 / Published: 9 March 2020
(This article belongs to the Special Issue Botulinum Neurotoxin Injection)
The purpose of this study is to evaluate the effects of botulinum toxin type A (BoNT-A) for managing sleep bruxism (SB) in a randomized, placebo-controlled trial. Thirty SB subjects were randomly assigned into two groups evenly. The placebo group received saline injections into each masseter muscle, and the treatment group received BoNT-A injections into each masseter muscle. Audio–video–polysomnographic recordings in the sleep laboratory were made before, at four weeks after, and at 12 weeks after injection. Sleep and SB parameters were scored according to the diagnostic and coding manual of American Academy of Sleep Medicine. The change of sleep and SB parameters were investigated using repeated measures analysis of variance (RM-ANOVA). Twenty-three subjects completed the study (placebo group 10, treatment group 13). None of the SB episode variables showed a significant time and group interaction (p > 0.05) except for electromyography (EMG) variables. The peak amplitude of EMG bursts during SB showed a significant time and group interaction (p = 0.001). The injection decreased the peak amplitude of EMG bursts during SB only in the treatment group for 12 weeks (p < 0.0001). A single BoNT-A injection cannot reduce the genesis of SB. However, it can be an effective management option for SB by reducing the intensity of the masseter muscle. View Full-Text
Keywords: botulinum toxin; sleep bruxism; polysomnography botulinum toxin; sleep bruxism; polysomnography
Show Figures

Figure 1

MDPI and ACS Style

Shim, Y.J.; Lee, H.J.; Park, K.J.; Kim, H.T.; Hong, I.H.; Kim, S.T. Botulinum Toxin Therapy for Managing Sleep Bruxism: A Randomized and Placebo—Controlled Trial. Toxins 2020, 12, 168.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop